Page last updated: 2024-12-06

sodium tungstate(vi)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sodium tungstate(VI), also known as sodium tungstate dihydrate, is an inorganic compound with the formula Na2WO4. It is a white, water-soluble solid that is commonly used as a catalyst and in the production of tungsten metal. Sodium tungstate(VI) can be synthesized by reacting tungsten trioxide (WO3) with sodium hydroxide (NaOH) in a reaction that can be represented by the following equation: WO3 + 2 NaOH → Na2WO4 + H2O. Sodium tungstate(VI) is used in various applications, such as in fireproofing agents, textile dyeing, and pigment production. It is also used in the production of tungsten alloys, which are known for their high strength and hardness. The compound is also used in the production of tungsten filament lamps. Sodium tungstate(VI) is a stable compound and is not known to be toxic. However, it is important to handle it with care, as it can be an irritant to the skin and eyes. Sodium tungstate(VI) is an important compound in the field of materials science and has been extensively studied for its properties and applications. Research on sodium tungstate(VI) focuses on its potential applications in various fields, including catalysis, energy storage, and nanomaterials. The compound's properties, such as its high melting point, good thermal stability, and ability to form various tungstate compounds, make it an attractive material for various technological applications.'

sodium tungstate(VI): inactivates molybdoenzymes in Anabaena; RN given refers to tungstic acid [H2WO4], di-Na salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sodium tungstate : An inorganic sodium salt having tungstate as the counterion. Combines with hydrogen peroxide for the oxidation of secondary amines to nitrones. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID26052
CHEBI ID63940
MeSH IDM0084699

Synonyms (44)

Synonym
disodium tetraoxatungstate(2-)
disodium tetraoxotungstate(2-)
chebi:63940 ,
tungstate, sodium
disodium dioxido(dioxo)tungsten
13472-45-2
disodium tetraoxotungstate (2-)
sodium tungstate (na2wo4)
tungastate (wo4(2-)), disodium, (t-4)-
sodium tungstate (na2(wo4))
disodium tungstate (na2wo4)
sodium wolframate
tungstic acid (h2wo4), disodium salt
einecs 236-743-4
sodium tungstate(vi) (na2wo4)
hsdb 5057
disodium tungstate
ccris 5814
disodium tetraoxatungstate (2-)
tungstic acid, disodium salt
sodium tungstate(vi)
tungstate (wo42-), disodium, (beta-4)-
disodium wolframate
sodium tungsten oxide (na2wo4)
sodium tungstate
tungstate (wo42-), disodium, (t-4)-
unii-64lrh4405g
64lrh4405g ,
ec 236-743-4
na2wo4
disodium tetraoxotungstate
sodium tetraoxotungstate(vi)
XMVONEAAOPAGAO-UHFFFAOYSA-N
sodium tungstate (vi)
sodium tungstate, reagent grade
sodium tungstate(vi) [mi]
tungstate (wo42-), sodium (1:2), (t-4)-
tungsten(4+) ion disodium dihydroxide dioxidandiide
GS-3112
AKOS030227979
sodiumtungstate(vi)
Q418410
disodium;dioxido(dioxo)tungsten
126752-51-0

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LD50 values for 1-14 days show that sodium metatungstate is significantly more toxic to fish than sodium tungstate."( Tungsten speciation and toxicity: acute toxicity of mono- and poly-tungstates to fish.
Christodoulatos, C; Koutsospyros, A; Strigul, N, 2010
)
0.36
" Based on histopathology effects seen in the kidneys, the lowest observable adverse effect level was 125 mg/kg/d and the no observable adverse effect level was 75 mg/kg/d in both sexes of rats for oral subchronic toxicity."( Subchronic Oral Toxicity of Sodium Tungstate in Sprague-Dawley Rats.
Bazar, MA; Crouse, LC; Leach, GJ; McCain, WC; Middleton, JR; Reddy, G; Roszell, LE,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" In the present report, pharmacokinetic studies with sodium tungstate were carried out in the Sprague-Dawley rat and beagle dog."( Pharmacokinetics of sodium tungstate in rat and dog: a population approach.
Bonnet, PA; Bressolle, F; Cros, G; de Richter, RK; Le Lamer, S; Poucheret, P, 2000
)
0.31
"In this paper, an empirical Bayes methodology was used to determine the pharmacokinetic profile of sodium tungstate in beagle dogs after multiple oral dosing using the P-PHARM computer program."( Estimation of pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in beagle dogs.
Bressolle, F; Cros, G; Fernändez-Alvarez, J; Le Lamer, S; Piñol, C; Serrano, JJ, 2001
)
0.31
"The purpose of this study was to use a population approach in the preclinical development program of sodium tungstate in the rat in order i) to compute individual pharmacokinetic parameters of this compound after repeated oral administrations, until the 4-week toxicology study, using an empirical Bayes methodology; and ii) to study the influence of the administered dose, of the gender and of the duration of treatment on the pharmacokinetic parameters."( An application of population kinetics analysis to estimate pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in rats.
Bressolle, F; Cros, G; Fernández-Alvarez, J; Le Lamer, S; Piñol, C, 2002
)
0.31
" An empirical Bayes methodology was used to compute individual pharmacokinetic parameters."( Influence of food and diabetes on pharmacokinetics of sodium tungstate in rat.
Bressolle, F; Cros, G; Le Lamer-Déchamps, S; Poucheret, P, 2002
)
0.31
" The pharmacokinetics of tungsten in most tissues was best described with a two-compartment pharmacokinetic model with initial phase half-lives of approximately 4 to 6 h and a longer terminal phase with half-lives of approximately 6 to 67 days."( Pharmacokinetics of radiolabeled tungsten ((188)W) in male Sprague-Dawley rats following acute sodium tungstate inhalation.
Chapman, GD; Dorman, DC; Leavens, TL; Olabisi, AO; Radcliffe, PM; Struve, MF; Tewksbury, E; Wagner, DJ; Wong, BA, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" In rat, bioavailability was high (92%), whereas it was lower in dog (approximately 65%)."( Pharmacokinetics of sodium tungstate in rat and dog: a population approach.
Bonnet, PA; Bressolle, F; Cros, G; de Richter, RK; Le Lamer, S; Poucheret, P, 2000
)
0.31
" The bioavailability was on an average 70%; being significantly higher in females than in males (0."( An application of population kinetics analysis to estimate pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in rats.
Bressolle, F; Cros, G; Fernández-Alvarez, J; Le Lamer, S; Piñol, C, 2002
)
0.31
" A significant relationship was found between the bioavailability and the status of the animals."( Influence of food and diabetes on pharmacokinetics of sodium tungstate in rat.
Bressolle, F; Cros, G; Le Lamer-Déchamps, S; Poucheret, P, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
"In this paper, an empirical Bayes methodology was used to determine the pharmacokinetic profile of sodium tungstate in beagle dogs after multiple oral dosing using the P-PHARM computer program."( Estimation of pharmacokinetic parameters of sodium tungstate after multiple-dose during preclinical studies in beagle dogs.
Bressolle, F; Cros, G; Fernändez-Alvarez, J; Le Lamer, S; Piñol, C; Serrano, JJ, 2001
)
0.31
" Adult male and female rats were orally dosed with diH(2)O vehicle, 5 or 125 mg/kg/day of sodium tungstate through mating, gestation, and weaning (PND 0-20)."( Neurobehavioral effects of sodium tungstate exposure on rats and their progeny.
Arfsten, D; Bekkedal, MY; Chapman, GD; Gunasekar, PG; McInturf, SM; Wilfong, E,
)
0.13
" Histopathological changes were observed in the kidneys of male and female rats dosed at 125 or 200 mg/k/d consisting of mild to severe cortical tubule basophilia in 2 high-dose groups."( Subchronic Oral Toxicity of Sodium Tungstate in Sprague-Dawley Rats.
Bazar, MA; Crouse, LC; Leach, GJ; McCain, WC; Middleton, JR; Reddy, G; Roszell, LE,
)
0.13
" For all metals, the dose-response curve followed a biphasic pattern that is typical of hormesis."( Thyroid Stem Cells But Not Differentiated Thyrocytes Are Sensitive to Slightly Increased Concentrations of Heavy Metals.
Franco, A; Gianì, F; Masto, R; Pandini, G; Trovato, MA; Vigneri, R, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
reagentA substance used in a chemical reaction to detect, measure, examine, or produce other substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
inorganic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (13.67)18.7374
1990's19 (13.67)18.2507
2000's45 (32.37)29.6817
2010's52 (37.41)24.3611
2020's4 (2.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.69 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.67%)5.53%
Reviews1 (0.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other148 (98.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]